Literature DB >> 27914489

Rationale and design of the East-West late lumen loss study: Comparison of late lumen loss between Eastern and Western drug-eluting stent study cohorts.

Robert W Harrison1, Vaishnavi Radhakrishnan2, Peter S Lam3, Dominic J Allocco3, Sandeep Brar4, Martin Fahy4, Rebecca Fisher5, Fumiaki Ikeno6, Philippe Généreux7, Takeshi Kimura8, Minglei Liu4, Weng Kit Lye2, Gary S Mintz7, Hirofumi Nagai9, Yuka Suzuki10, Roseann White11, John C Allen2, Mitchell W Krucoff5.   

Abstract

BACKGROUND: The contemporary evaluation of novel drug-eluting stents (DES) includes mechanistic observations that characterize postdeployment stent behavior. Quantification of late lumen loss due to neointimal hyperplasia 8-13 months after stent implantation, via quantitative coronary angiography (QCA), constitutes such an observation and is required by most regulatory authorities. Late lumen loss, as determined by QCA, has been validated as a surrogate for clinical endpoints such as target vessel revascularization. The mechanistic response to DES has not been directly compared across predominantly Asian or Western populations, whereas understanding their comparability across geographic populations could enhance global DES evaluation.
OBJECTIVE: The East-West late lumen loss study is designed to demonstrate whether the residual differences in late lumen loss, as assessed by QCA, is different between Eastern and Western DES recipients from studies with protocol angiography at 8-13 months of follow-up.
METHODS: Data from independent core laboratories that have characterized angiographic late lumen loss in DES clinical trials with protocol follow-up angiography will be compiled and dichotomized into Eastern and Western populations. A prospectively developed propensity score model incorporating clinical and anatomic variables affecting late lumen loss will be used to adjust comparisons of QCA measurements.
CONCLUSION: Documentation of whether there are clinically meaningful differences in mechanistic response to DES implantation across genetically unique geographies could facilitate both the quality and efficiency of global device evaluation requiring invasive follow-up for novel stent designs. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27914489     DOI: 10.1016/j.ahj.2016.07.011

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

Review 1.  Methods to assess bioresorbable vascular scaffold devices behaviour after implantation.

Authors:  Alberto Pernigotti; Elisabetta Moscarella; Giosafat Spitaleri; Claudia Scardino; Kohki Ishida; Salvatore Brugaletta
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

2.  Inter- and intra-core laboratory variability in the quantitative coronary angiography analysis for drug-eluting stent treatment and follow up.

Authors:  Shigenori Ito; Kanako Kinoshita; Akiko Endo; Ryoko Kami; Yuko Kotake; Masato Nakamura
Journal:  Ther Adv Cardiovasc Dis       Date:  2020 Jan-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.